Disposition of soy isoflavones in normal human breast tissue.
Abstract
[BACKGROUND] Despite decades of research on the relation between soy and breast cancer, questions regarding the absorption, metabolism, and distribution of isoflavones in breast tissue largely remain unanswered.
[OBJECTIVE] We evaluated the potential health effects of isoflavone consumption on normal breast tissue; isoflavone concentrations, metabolites, and biodistribution were investigated and compared with 17beta-estradiol exposure.
[DESIGN] In this dietary intervention study, healthy women were randomly allocated to a soy milk (n = 11; 16.98-mg genistein and 5.40-mg daidzein aglycone equivalents per dose), soy supplement (n = 10; 5.27-mg genistein and 17.56-mg daidzein aglycone equivalents per dose), or control (n = 10) group. After a run-in period > or = 4 d, 3 doses of soy milk or soy supplements were taken daily for 5 d before an esthetic breast reduction. Blood and breast biopsies were collected during surgery and analyzed with liquid chromatography-tandem mass spectrometry.
[RESULTS] After soy administration, genistein and total daidzein concentrations, which were expressed as aglycone equivalents, ranged from 135.1 to 2831 nmol/L and 105.1 to 1397 nmol/L, respectively, in hydrolyzed serum and from 92.33 to 493.8 pmol/g and 22.15 to 770.8 pmol/g, respectively, in hydrolyzed breast tissue. The major metabolites identified in nonhydrolyzed samples were genistein-7-O-glucuronide and daidzein-7-O-glucuronide, with an overall glucuronidation of 98%. Total isoflavones showed a breast adipose/glandular tissue distribution of 40:60, and their mean (+/-SEM) derived 17beta-estradiol equivalents toward estrogen receptor beta were 21 +/- 4-fold and 40 +/- 10-fold higher than the 17beta-estradiol concentrations in adipose (0.283 +/- 0.089 pmol/g, P < 0.001) and glandular (0.246 +/- 0.091 pmol/g, P = 0.001) fractions, respectively.
[CONCLUSION] After intake of soy milk and soy supplements, isoflavones reach exposure levels in breast tissue at which potential health effects may occur.
[OBJECTIVE] We evaluated the potential health effects of isoflavone consumption on normal breast tissue; isoflavone concentrations, metabolites, and biodistribution were investigated and compared with 17beta-estradiol exposure.
[DESIGN] In this dietary intervention study, healthy women were randomly allocated to a soy milk (n = 11; 16.98-mg genistein and 5.40-mg daidzein aglycone equivalents per dose), soy supplement (n = 10; 5.27-mg genistein and 17.56-mg daidzein aglycone equivalents per dose), or control (n = 10) group. After a run-in period > or = 4 d, 3 doses of soy milk or soy supplements were taken daily for 5 d before an esthetic breast reduction. Blood and breast biopsies were collected during surgery and analyzed with liquid chromatography-tandem mass spectrometry.
[RESULTS] After soy administration, genistein and total daidzein concentrations, which were expressed as aglycone equivalents, ranged from 135.1 to 2831 nmol/L and 105.1 to 1397 nmol/L, respectively, in hydrolyzed serum and from 92.33 to 493.8 pmol/g and 22.15 to 770.8 pmol/g, respectively, in hydrolyzed breast tissue. The major metabolites identified in nonhydrolyzed samples were genistein-7-O-glucuronide and daidzein-7-O-glucuronide, with an overall glucuronidation of 98%. Total isoflavones showed a breast adipose/glandular tissue distribution of 40:60, and their mean (+/-SEM) derived 17beta-estradiol equivalents toward estrogen receptor beta were 21 +/- 4-fold and 40 +/- 10-fold higher than the 17beta-estradiol concentrations in adipose (0.283 +/- 0.089 pmol/g, P < 0.001) and glandular (0.246 +/- 0.091 pmol/g, P = 0.001) fractions, respectively.
[CONCLUSION] After intake of soy milk and soy supplements, isoflavones reach exposure levels in breast tissue at which potential health effects may occur.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 해부 | breast
|
유방 | dict | 9 | |
| 시술 | breast reduction
|
유방성형술 | dict | 1 | |
| 해부 | Blood
|
scispacy | 1 | ||
| 해부 | serum
|
scispacy | 1 | ||
| 해부 | pmol/g
|
scispacy | 1 | ||
| 해부 | breast adipose/glandular tissue
|
scispacy | 1 | ||
| 해부 | adipose
|
scispacy | 1 | ||
| 약물 | Disposition of soy isoflavones
|
scispacy | 1 | ||
| 약물 | isoflavones
|
C0022179
Isoflavones
|
scispacy | 1 | |
| 약물 | isoflavone
|
C0022179
Isoflavones
|
scispacy | 1 | |
| 약물 | 17beta-estradiol
|
scispacy | 1 | ||
| 약물 | genistein
|
C0061202
genistein
|
scispacy | 1 | |
| 약물 | daidzein aglycone
|
scispacy | 1 | ||
| 약물 | daidzein
|
C0057090
daidzein
|
scispacy | 1 | |
| 약물 | aglycone equivalents
|
scispacy | 1 | ||
| 약물 | nmol/L
|
C0439282
Nanomole/liter
|
scispacy | 1 | |
| 약물 | daidzein-7-O-glucuronide
|
scispacy | 1 | ||
| 약물 | estrogen
|
C0014939
estrogens
|
scispacy | 1 | |
| 약물 | [BACKGROUND]
|
scispacy | 1 | ||
| 약물 | [OBJECTIVE]
|
scispacy | 1 | ||
| 약물 | [DESIGN]
|
scispacy | 1 | ||
| 약물 | aglycone
|
scispacy | 1 | ||
| 약물 | 40:60
|
scispacy | 1 | ||
| 질환 | breast cancer
|
C0006142
Malignant neoplasm of breast
|
scispacy | 1 | |
| 질환 | breast adipose/glandular
|
scispacy | 1 | ||
| 질환 | breast tissue
|
scispacy | 1 | ||
| 질환 | breast biopsies
|
scispacy | 1 | ||
| 기타 | human breast tissue
|
scispacy | 1 | ||
| 기타 | women
|
scispacy | 1 | ||
| 기타 | estrogen receptor beta
|
scispacy | 1 | ||
| 기타 | glandular
|
scispacy | 1 |
MeSH Terms
Adipose Tissue; Adolescent; Adult; Breast; Chromatography, Liquid; Dietary Supplements; Estradiol; Estrogen Receptor beta; Female; Genistein; Humans; Isoflavones; Mammary Glands, Human; Middle Aged; Phytoestrogens; Plant Extracts; Reference Values; Soy Foods; Glycine max; Tandem Mass Spectrometry; Tissue Distribution; Young Adult
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- The impact of three-dimensional simulation and virtual reality technologies on surgical decision-making and postoperative satisfaction in aesthetic surgery: a preliminary study.
- Cutaneous fistula of the breast: A complication of cosmetic autologous fat transfer.
- Epidermal inclusion cyst after breast reduction mammoplasty.
- Clinical outcomes of synthetic absorbable mesh use in breast surgery: First case series in reconstruction and aesthetic mastopexy.
- Implant-based versus autologous mastopexy after massive weight loss: Complications and patient satisfaction.